Trials explorer

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Trial of RSC-1255 for Treatment of Patients With Advanced Malignancies is being studied. Conditions: Advanced Malignant Solid Neoplasm, RAS Mutation, Lung Cancer +3 • Eligibility: Inclusion Criteria (Key Factors): 1. Has pathologically confirmed advanced or metastatic malignancy characterized by one or more of the following: * Participant is intolerant of existing therapy(ies) known…. Goal: RSC-101 is a Phase 1a/1b clinical trial of RSC-1255 in adult study participants with advanced solid tumor malignancies who are intolerant of existing therapies known to provide clinical benefit, have disease that has progressed after standard therapy, or have previously failed other therapies. The study has two phases. Phase/Status/Sponsor: Unknown phase; RECRUITING; RasCal Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Autologous T-cells Genetically Engineered to Express Receptors Reactive Against KRAS Mutations in Conjunction With a Vaccine Directed Against These Antigens in Participants With Metastatic Cancer is being studied. Conditions: Metastatic Solid Cancers, Colorectal Cancer, Breast Cancer +4 • Eligibility: * INCLUSION CRITERIA: * Participants with an appropriate HLA match for available Surgery Branch KRAS TCRs with evaluable metastatic solid cancer (e.g., gastrointestinal, genitourinary, breast, ovarian, non-small cell…. Goal: Background: Many cancer cells produce substances called antigens that are unique to each cancer. These antigens stimulate the body s immune responses. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Cognitive Aftereffects of Neurotoxicity in Children and Young Adults With Relapsed/Refractory Hematologic Malignancies Who Receive CAR T-cell Therapy is being studied. Conditions: Lymphoma, Leukemia • Eligibility: * INCLUSION CRITERIA: * Participants with disease * Participants are diagnosed with relapsed/refractory leukemias or lymphomas, and are scheduled to receive CAR T-cell treatment in one of the…. Goal: Background: CAR T-cell therapy is a promising new treatment for blood cancers. During treatment, a person s T-cells are genetically changed to kill cancer cells. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This open-label, multicenter trial is testing whether the radiopharmaceutical drug [177Lu]Lu-DOTATATE helps adults whose brain meningioma (WHO grade 1–3) has progressed after prior treatment, compared with the standard of care. Participants are randomly assigned 2:1 to receive either [177Lu]Lu-DOTATATE or the standard therapy chosen by their doctor, and those on the standard arm may cross over to the radiopharmaceutical if their disease worsens. The study aims to learn whether [177Lu]Lu-DOTATATE can slow or stop tumor growth and how its safety compares with usual treatments. Key exclusions include NF2-related schwannomatosis, radiation-associated meningioma, prior SSTR2-targeted therapy, active infection, and significant cardiovascular disease.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Diagnosing and Treating Low Blood Sugar Levels is being studied. Conditions: Hypoglycemia, Insulinoma • Eligibility: * INCLUSION CRITERIA: In order to be eligible to participate in this study, an individual must meet all of the following criteria: 1. Male, females ages \>= 18.…. Goal: Hypoglycemia is the term used to refer to lower than normal levels of blood sugar. This study will continue to research the causes of hypoglycemia. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The trial tests whether regorafenib given as maintenance therapy after first-line treatment helps keep bone sarcoma from coming back. Participants are patients 12 years and older with confirmed primary bone sarcoma who have completed standard treatment and have no evidence of disease; they are randomized to regorafenib for up to 12 months or to placebo surveillance. The main goal is to see if regorafenib improves relapse-free survival and disease control, with results analyzed by high-risk versus low-risk relapse groups. Key exclusions include prior VEGFR inhibitors, certain cardiovascular problems, active infections, HIV, hepatitis B/C, pregnancy, and other conditions that could affect safety or adherence. The study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests regorafenib plus best supportive care as maintenance therapy for high-grade bone sarcomas after standard treatment. - It is for patients aged 12 and older with confirmed high-grade bone tumors (e.g., osteosarcoma, Ewing, chondrosarcoma, UPS, leiomyosarcoma, angiosarcoma) who have evaluable residual disease that cannot be removed and did not progress after initial therapy. - Participants will receive regorafenib with BSC for up to 12 months to see if this approach can better delay progression, with progression-free rate as a key measure. - Key exclusions include prior VEGFR inhibitors, soft tissue sarcomas, certain cardiovascular problems, active infection, and pregnancy or breastfeeding.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests whether interrupting aromatase inhibitor therapy is feasible and how it compares to continuing AI therapy in adults with locally advanced or metastatic low-grade endometrial stromal sarcoma (LGESS) who have disease controlled on AI. It is open-label and randomized, aiming to learn the effect on progression-free survival. It includes adults aged 18 and older with LGESS whose disease is controlled at randomisation while on AI for at least 24–36 months. Key exclusions include pregnancy or breastfeeding, use of other anticancer drugs, and significant cardiovascular, liver, kidney, or other major illnesses that could interfere with participation. Ancillary studies will explore predictive factors and collect sociobehavioral data from participants.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

HSV G207 in Children With Recurrent or Refractory Cerebellar Brain Tumors is being studied. Conditions: Neoplasms, Brain, Glioblastoma Multiforme, Glioblastoma of Cerebellum +30 • Eligibility: Inclusion Criteria: * Age ≥ 36 months and \< 22 years * Pathologically proven malignant cerebellar brain tumor (including medulloblastoma, glioblastoma multiforme, giant cell glioblastoma, anaplastic astrocytoma, primitive…. Goal: This study is a clinical trial to determine the safety of inoculating G207 (an experimental virus therapy) into a recurrent or refractory cerebellar brain tumor. The safety of combining G207 with a single low dose of radiation, designed to enhance virus replication, tumor cell killing, and an anti-tumor immune response, will also be tested. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Long-term Evaluation and Follow-up Care of Patients Treated With Stem Cell Transplants is being studied. Conditions: Graft-versus-leukemia, Graft vs Host Disease, Graft Rejection • Eligibility: * INCLUSION CRITERIA-TRANSPLANT RECIPIENTS: Patients surviving three years or more from date of first stem cell transplant who have been treated. -With an experimental allogeneic stem cell transplant…. Goal: This study will provide follow-up evaluation and care of patients who have undergone allogeneic (donor) stem cell transplantation at the NIH Clinical Center. Patients are monitored for their response to treatment, disease relapse, and later-occurring effects of the transplant. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Heart, Lung, and Blood Institute (NHLBI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS) is being studied. Conditions: KSHV Inflammatory Cytokine Syndrome (KICS), KSHV, HHV-8 • Eligibility: * INCLUSION CRITERIA: * Age greater than or equal to18 Years. * Any HIV status. * At least two manifestations drawn from at least two of the categories…. Goal: Background: \- KSHV inflammatory cytokine syndrome (KICS) is a newly recognized disease caused by Kaposi sarcoma-associated herpesvirus (KSHV). This virus can cause cancer. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer is being studied. Conditions: Extensive-stage Small-cell Lung Cancer • Eligibility: Inclusion Criteria: * Have histologically or cytologically confirmed ES-SCLC (using the AJCC \[American Joint Committee on Cancer\] tumor node metastasis staging system combined with Veterans Administration Lung Study…. Goal: This is a Phase III, multisite, randomized, double-blinded study to investigate pumitamig (BNT327) combined with chemotherapy (etoposide/carboplatin) compared to atezolizumab combined with chemotherapy (etoposide/carboplatin) for the treatment of participants with previously untreated extensive-stage small-cell lung cancer (ES-SCLC). Phase/Status/Sponsor: Unknown phase; RECRUITING; BioNTech SE.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

"Constitution of a Biological Collection to Establish Preclinical Translational Models for the Study of Tumors and Chronic Liver Diseases". is being studied. Conditions: Chronic Liver Disease and Cirrhosis, Liver Cancer, Non-Alcoholic Fatty Liver Disease +4 • Eligibility: Inclusion Criteria: 1. Patients * diagnosed with chronic liver disease (viral or not) * diagnosed with at least one liver nodule for which a biopsy is planned as…. Goal: Development of preclinical translational models for chronic liver tumors and diseases study, such as spheroids cultured in autologous medium and murine xenograft models to test the efficacy of new therapeutic strategies. Phase/Status/Sponsor: Unknown phase; RECRUITING; Institut National de la Santé Et de la Recherche Médicale, France.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II Randomized, Open Label Non-inferiority Study of NiraParib Maintenance After 3 vs. 6 Cycles of Platinum-based Chemotherapy in completeLy debUlked Advanced HRDpositive High-grade Ovarian Cancer patientS in First Line Therapy is being studied. Conditions: Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinoma +1 • Eligibility: Inclusion Criteria: 1. Written informed consent and obtained from the subject prior to performing any protocol-related procedures, including screening evaluations. 2. Female patient, age ≥ 18 years. 3.…. Goal: Multicenter, randomized, open label study including patients with advanced HRDpositive high-grade ovarian cancer, fallopian tube cancer, primary peritoneal cancer and clear cell carcinoma of the ovary with no residual tumor mass following primary tumor debulking to determine recurrence free survival in patients treated with 3 cycles carboplatin + paclitaxel and maintenance therapy with niraparib vs. 6 cycles carboplatin + paclitaxel and maintenance therapy with niraparib. Phase/Status/Sponsor: Unknown phase; RECRUITING; North Eastern German Society of Gynaecological Oncology.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

AVI Didactic Experience for Latinx Patient Treatment Adherence and Non-English Speaker Trial Enrollment Study in Rad Onc is being studied. Conditions: Breast Cancer Invasive, Prostate Cancer • Eligibility: Pilot Phase Inclusion Criteria: 1. Spanish speakers of Latinx background as defined by the U.S. Census Bureau as anyone from Mexican, Puerto Rican, Cuban, Dominican, Central or South…. Goal: The study aims to develop educational media interventions to prepare Latinx Spanish-speaking radiation oncology patients for a course of breast or prostate cancer radiation therapy and to foster receptivity and informed decision-making around cancer clinical trial participation. Phase/Status/Sponsor: Unknown phase; RECRUITING; Columbia University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Selinexor in Combination With R-CHOP as the First-line Therapy for TP53-mutated DLBCL Patients (Smart Trial) is being studied. Conditions: Diffuse Large B Cell Lymphoma • Eligibility: Inclusion Criteria: * Subjects fully understand and voluntarily participate in this study and sign informed consent. * Aged ≥18 and ≤80 years, no gender limitation. * Histologically confirmed…. Goal: This is a prospective, single-arm, multi-center, phase II clinical trial to evaluate the efficacy and safety of selinexor in combination with R-CHOP (rituximab, cyclophosphamide, vincristine, doxorubicin, and prednisone) followed by selinexor maintenance for untreated TP53-mutated diffuse large B-cell lymphoma (DLBCL) patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sun Yat-sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests ultrasound-based brain imaging and stimulation to help understand and improve consciousness in people with disorders of consciousness after severe brain injury. - It targets adults with DOC, specifically Unresponsive Wakefulness Syndrome (UWS) or Minimally Conscious State (MCS), and uses bedside ultrasound to capture brain structure and function in real time. - The researchers want to learn how ultrasound measurements relate to the level of consciousness and how ultrasound settings could be tailored to each patient to support recovery. - Eligibility includes adults 18 or older with DOC after severe brain injury, and a key exclusion is ongoing mechanical ventilation. - The study plans to enroll about ten patients for the first aims.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Study to Investigate the Efficacy and Safety of an Investigational Combination Therapy With BNT324 and BNT327 in Patients With Advanced Lung Cancer is being studied. Conditions: Advanced Lung Cancer • Eligibility: Inclusion Criteria: * Aged ≥18 years at the time of giving informed consent. * Histological or cytological confirmed unresectable advanced/metastatic lung cancer. Histological classification may be based on…. Goal: This study aims to investigate the combination of BNT324, a B7-H3 antibody-drug conjugate (ADC) with BNT327, a programmed death-ligand 1 (PD-L1) and vascular endothelial growth factor (VEGF) bispecific antibody, in participants with advanced/metastatic or relapsed/progressive small cell lung cancer (SCLC) and non small cell lung cancer (NSCLC). Phase/Status/Sponsor: Unknown phase; RECRUITING; BioNTech SE.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Metastases Free Survival With Saruparib vs Placebo Added to a Standard RT/ADT in Men With High-risk Prostate Cancer With a BRCA Mutation is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Male participants with a histologically documented diagnosis of prostate adenocarcinoma. * Newly diagnosed high-risk and very high-risk (localised/locally advanced) prostate cancer or a high-risk biochemical…. Goal: The purpose of the study is to demonstrate superiority of Saruparib (AZD5305) relative to placebo added to a standard radiation therapy (RT) + androgen deprivation therapy (ADT) regimen by assessment of metastases-free survival in participants with high-risk and very high-risk localised/locally advanced prostate cancer with a breast cancer gene mutation (BRCAm). Phase/Status/Sponsor: Unknown phase; RECRUITING; AstraZeneca.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors is being studied. Conditions: Solid Tumor, Advanced Solid Tumor, Solid Tumor, Adult +25 • Eligibility: Inclusion Criteria: \- Must have a pathologically confirmed advanced and unresectable or metastatic solid tumor listed below with documented disease progression on last standard treatment. Part 1 only:…. Goal: The goal of the Dose Escalation phase of the study is to evaluate the safety, tolerability, pharmacokinetics (PK) and preliminary anti-tumor activity to determine the preliminary recommended dose for expansion (RDE) of NKT3964 in adults with advanced or metastatic solid tumors. The goal of the Expansion phase of the study is to evaluate the preliminary anti-tumor activity of NKT3964 at the RDE based on objective response rate (ORR) and determine the preliminary recommended Phase 2 dose (RP2D). Phase/Status/Sponsor: Unknown phase; RECRUITING; NiKang Therapeutics, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests maintenance therapy with letrozole and abemaciclib for adults with ER-positive, mismatch repair–proficient, TP53 wild-type endometrial cancer that has advanced or recurred after initial carboplatin/paclitaxel chemotherapy (with or without anti-PD-(L)1 therapy). - It is a single-arm phase 2 trial at Dana-Farber Cancer Institute, enrolling about 32 participants, with treatment for up to 2 years and follow-up for 3 years after treatment ends. - Eligible participants must have ER-positive, MMR-proficient, TP53 wild-type disease and have completed a defined amount of prior chemotherapy; key exclusions include prior CDK4/6 inhibitor treatment, active brain metastases, pregnancy, and certain drug interactions with CYP3A4. - The study will monitor safety and effectiveness using imaging and laboratory tests to learn whether this drug combination helps control the cancer in this specific group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Roginolisib (IOA-244) With Venetoclax and Rituximab for Refractory/Relapsed Chronic Lymphocytic Leukemia (CLL) is being studied. Conditions: Leukemia, Relapsed Leukemia, Chronic Lymphocytic Leukemia +2 • Eligibility: Inclusion Criteria: * Patients with relapsed/refractory CLL who meet iwCLL criteria for requiring treatment. * Patients with measurable disease as defined by at least one of: circulating lymphocytosis…. Goal: This research study will test the safety and anticancer activity of the combination of three drugs (Roginolisib, Venetoclax, and Rituximab) for participants with relapsed or refractory Chronic Lymphocytic Leukemia (CLL). The names of the study drugs involved in this study are: * Roginolisib (a novel type of PI3-kinase delta inhibitor) * Venetoclax (a type of B-cell lymphoma 2 inhibitor) * Rituximab (a type of monoclonal antibody) Phase/Status/Sponsor: Unknown phase; RECRUITING; Jennifer R. Brown, MD, PhD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Sarah Nanotechnology System for Treatment of Advanced Metastatic Solid Tumors Using Hyperthermia. is being studied. Conditions: Metastatic Solid Tumors, Stage 4 Cancer • Eligibility: Inclusion Criteria: 1. Life expectancy of at least 90 days. 2. Histologically confirmed advanced metastatic solid tumors located between the thoracic inlet and the pelvic floor, that have…. Goal: This is a sequential, dose-escalation, non-randomized, prospective, early feasibility trial. The goal of this clinical trial is to gather information on the safety and the recommended dose of the Sarah Nanotechnology System. Phase/Status/Sponsor: Unknown phase; RECRUITING; New Phase Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

BBO-11818 in Adult Subjects With KRAS Mutant Cancer is being studied. Conditions: Non-Small Cell Lung Cancer, NSCLC, PDAC - Pancreatic Ductal Adenocarcinoma +11 • Eligibility: Inclusion Criteria: * Histologically documented locally advanced and unresectable or metastatic NSCLC, PDAC, CRC, or other solid tumor with KRAS G12A, G12C, G12D, G12S, or G12V mutation *…. Goal: A first in human study to evaluate the safety and preliminary antitumor activity of BBO-11818, a pan-KRAS inhibitor, in subjects with locally advanced unresectable or metastatic KRAS mutant solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Polymeric Micellar Paclitaxel for Metastatic Pancreatic Cancer is being studied. Conditions: Pancreatic Cancer Metastatic • Eligibility: Inclusion Criteria: * 1\) Men or women aged 18 to 75 years old (including the critical value). * 2）Metastatic pancreatic cancer confirmed by histology or cytology. * 3）Patients…. Goal: This trial is a multi-center, randomized, open, parallel-group and positive-controlled phase III trial to evaluate the efficacy and safety of paclitaxel polymeric micelles for injection plus gemcitabine as first-line treatment of metastatic pancreatic cancer compared with nab-Paclitaxel plus gemcitabine. Phase/Status/Sponsor: Unknown phase; RECRUITING; Shanghai Yizhong Pharmaceutical Co., Ltd..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Rhomboid Intercostal Sub-serratus Plane Blocks and Erector Spinae Plane Block in Mastectomy Surgeries is being studied. Conditions: Breast Cancer • Eligibility: Inclusion Criteria: 1. Breast cancer female patients. 2. ASA class II and III. 3. Age ≥ 18 and ≤ 60 Years. 4. Body mass index (BMI): \> 20…. Goal: Acute post-mastectomy pain can cause adverse impacts on the patients as delayed discharge from post-operative recovery area, impairs pulmonary and immune functions, increases risk of ileus, thromboembolism, myocardial infarction and may lead to increased length of hospital stay. It is also an important factor leading to the development of chronic post mastectomy pain syndrome (PMPS) in almost half of the patients. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute, Egypt.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) is being studied. Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer +27 • Eligibility: Inclusion Criteria: * At least 18 years of age or 12 to 17 years of age after Safety Review Committee approval. * Locally advanced or metastatic solid malignancy…. Goal: The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; PMV Pharmaceuticals, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a first-in-human Phase 1 study of STX-0712 to test its safety and early signs of activity in adults with advanced CMML or relapsed/refractory monocytic AML who have no other approved treatment options. The trial is open-label and non-randomized, with two parts: dose escalation to find safe dose levels, then dose expansion to further assess safety and preliminary efficacy. Participants receive a single intravenous infusion of STX-0712 every 21 days and stay on treatment until stopping criteria are met, with safety, PK, PD, and early efficacy data collected. Key exclusions include acute promyelocytic leukemia or extramedullary AML, active infections, recent stem cell transplant or major immunosuppressive therapy, significant cardiovascular disease or QT prolongation, and active HIV or HBV/HCV or other cancers requiring therapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Dyadic Co-learning Intervention for Patients With Prostate Cancer and Their Spouses is being studied. Conditions: Prostate Cancer (Adenocarcinoma) • Eligibility: Inclusion Criteria: For Patients: 1. Diagnosed with prostate cancer by a board-certified urologist. 2. Has either decided on a treatment plan or completed treatment within the past two…. Goal: This study aims to help patients with prostate cancer and their spouses cope better with the challenges of cancer by learning and supporting each other together. The investigators will test an 8-week "Dyadic Co-learning Intervention," which includes weekly learning topics, a mobile app, and professional support. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Taipei University of Nursing and Health Sciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PD-1 Antibody Plus GEMOX as Postoperative Adjuvant Therapy in Perihilar Cholangiocarcinoma is being studied. Conditions: Perihilar Cholangiocarcinoma • Eligibility: Inclusion Criteria: 1. The patient must sign an informed consent form; 2. Age 18-75 years old, both male and female; 3. ECOG performance status score (PS score) 0…. Goal: This is an open-label,single center,non-randomized,single arm exploratory study. The objective of this study is to evaluate the efficacy and safety of PD-1 antibody plus GEMOX as postoperative adjuvant therapy in perihilar cholangiocarcinoma with positively metastatic lymph nodes. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Assessment of Skin Lesions Using a Tissue Oxygen Imager Based on Protoporphyrin IX (PPIX) Fluorescence. This is an Open-label, Non-randomized, Feasibility Study That Includes a One-time Application of an FDA Approved Medication Followed by Local Imaging for Benign Skin Growth and Lesions Clinically is being studied. Conditions: Non-Melanoma Skin Cancer (NMSC), Benign Skin Growth • Eligibility: Inclusion Criteria: * Adults ≥ 18 years of age. * Histologic proof of non-melanoma skin cancer. Patients with different skin tones based on the Fitzpatrick Scale, who present…. Goal: The primary objective of this study is the evaluation of the efficacy of the tissue oxygen imager based on PpIX DF in differentiating benign skin growth from non-melanoma skin cancer (NMSC). Phase/Status/Sponsor: Unknown phase; RECRUITING; Dartmouth-Hitchcock Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Binary Oncolytic Adenovirus in Combination With HER2-Specific Autologous CAR VST, Advanced HER2 Positive Solid Tumors is being studied. Conditions: Bladder Cancer, Head and Neck Squamous Cell Carcinoma, Cancer of the Salivary Gland +7 • Eligibility: Inclusion Criteria: This study will look at solid tumors (as a basket trial for any solid cancer) with HER2 positivity based on IHC Procurement Inclusion Criteria 1. The…. Goal: This study is a first in human Phase 1 study that involves patients with a type of cancer called HER2 (Human Epidermal Growth Factor Receptor 2) positive cancer. This study asks patients to volunteer to take part in a research study investigating the safety and efficacy of using special immune cells called HER2 chimeric antigen receptor specific cytotoxic T lymphocytes (HER2 specific CAR T cells), in combination with intra-tumor injection of CAdVEC, an oncolytic adenovirus that is designed to help the immune system including HER2 specific CAR T cell react to the tumor. Phase/Status/Sponsor: Unknown phase; RECRUITING; Baylor College of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Clinical Trial to Evaluate EDV Nanocell Therapy With Gemcitabine and Nab-paclitaxel in Pancreatic Cancer is being studied. Conditions: Pancreatic Cancer, Metastatic, PDAC - Pancreatic Ductal Adenocarcinoma • Eligibility: Inclusion Criteria: * Histological or pathological confirmation of metastatic pancreas adenocarcinoma. Cytological or histological evidence of metastatic disease is required. * Male or Female greater than or equal…. Goal: The purpose of this study is to evaluate the safety and tolerability and overall survival (OS) of E-EDV-D682/GC in combination with gemcitabine and nab-paclitaxel versus gemcitabine and nab-paclitaxel alone in participants with metastatic pancreatic ductal adenocarcinoma (PDAC) who have progressed on therapy. Phase/Status/Sponsor: Unknown phase; RECRUITING; Engeneic Pty Limited.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Anti-Lag-3 (Relatlimab) and Anti-PD-1 Blockade (Nivolumab) Versus Standard of Care (Lomustine) for the Treatment of Patients With Recurrent Glioblastoma is being studied. Conditions: Progressive Glioblastoma, Recurrent Glioblastoma • Eligibility: Inclusion Criteria: * Histologically-proven glioblastoma (World Health Organization \[WHO\] 2021 criteria) * Progressive or recurrent disease per Response Assessment in Neuro-Oncology (RANO) criteria * No IDH mutation (IDH1…. Goal: This phase II trial compares the safety, side effects and effectiveness of anti-lag-3 (relatlimab) and anti-PD-1 blockade (nivolumab) to standard of care lomustine for the treatment of patients with glioblastoma that has come back after a period of improvement (recurrent). Relatlimab is a monoclonal antibody that may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests whether adding durvalumab to the chemotherapy drugs gemcitabine and cisplatin given before surgery helps treat high-risk, resectable intrahepatic cholangiocarcinoma (liver cancer). - It is for adults who are considered candidates for curative surgery. - Researchers want to learn how many patients can complete the pre-surgery therapy and then have the tumor completely removed, as well as rates of major tumor response and overall survival after treatment. - Key exclusions include pregnancy, active autoimmune diseases, active infections (including hepatitis B or C), recent major surgery or current immunosuppressive therapy, and other conditions that could affect safety or results.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether adding pembrolizumab, an immunotherapy drug, to the usual platinum-based chemotherapy after surgery helps people with certain stages of non-small cell lung cancer live longer without the cancer returning. - It is for adults who have had complete surgical removal of stage IIA-IIIB NSCLC (T3-4N2) and who have not received prior systemic treatment for this cancer. - The study compares two timing strategies: pembrolizumab after chemotherapy versus pembrolizumab given at the same time as chemotherapy, to see which approach improves disease-free and overall survival and how it affects side effects and quality of life. - Key eligibility notes include no active autoimmune disease requiring systemic therapy in the past 2 years, no active infection or pneumonitis, not pregnant, and adequate organ function; people with controlled HIV may participate under certain conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Biobank for Cholestatic Liver Diseases. is being studied. Conditions: Primary Sclerosing Cholangitis, Primary Biliary Cirrhosis, Cholangiocarcinoma +1 • Eligibility: Inclusion Criteria: PSC * Patients diagnosed with PSC and who are between the age of 18 and 85 at time of enrollment in the study. * The diagnosis…. Goal: This study is a biobank of specimens and clinical data for use in current and future research to better understand the cholestatic liver diseases primary biliary cirrhosis/cholangitis (PBC) and primary sclerosing cholangitis (PSC). Phase/Status/Sponsor: Unknown phase; RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Radiation Medication (Radium-223 Dichloride) Versus Radium-223 Dichloride Plus Radiation Enhancing Medication (M3814) Versus Radium-223 Dichloride Plus M3814 Plus Avelumab (a Type of Immunotherapy) for Advanced Prostate Cancer Not Responsive to Hormonal Therapy is being studied. Conditions: Metastatic Castration-Resistant Prostate Carcinoma, Metastatic Malignant Neoplasm in the Bone, Metastatic Malignant Neoplasm in the Lymph Nodes +1 • Eligibility: Inclusion Criteria: * PHASE 1: Eastern Cooperative Oncology Group (ECOG) performance status =\< 1 (Karnofsky \>= 70%) * PHASE 2: ECOG performance status =\< 2 (Karnofsky \>= 60%)…. Goal: This phase I/II trial studies the best dose of M3814 when given together with radium-223 dichloride or with radium-223 dichloride and avelumab and to see how well they work in treating patients with castrate-resistant prostate cancer that had spread to other places in the body (metastatic). M3814 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests adding the drug ruxolitinib to standard graft-versus-host disease (GVHD) prevention around an allogeneic stem cell transplant for older adults with myelofibrosis or MDS/MPN overlap syndromes. It has two parts: before, during, and after transplant, with ruxolitinib started before conditioning and continued for up to about a year (with taper) along with standard GVHD meds. It is for adults who are candidates for allogeneic HCT and have MF or MDS/MPN overlap, with most participants up to age 75 (some over 75 if health criteria are met). Key exclusions include contraindication to ruxolitinib, active uncontrolled infections, HIV, untreated TB, pregnancy, or a history of prior allogeneic transplant, and recent MI, stroke, or unprovoked clotting within 6 months.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study is being studied. Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma • Eligibility: Inclusion Criteria: * Participants must have a confirmed diagnosis of chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) (collectively referred to as CLL throughout) according to the…. Goal: This phase III trial compares early treatment with venetoclax and obinutuzumab versus delayed treatment with venetoclax and obinutuzumab in patients with newly diagnosed high-risk chronic lymphocytic leukemia or small lymphocytic lymphoma. Venetoclax is in a class of medications called B-cell lymphoma-2 (BCL-2) inhibitors. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma is being studied. Conditions: Endometrial Adenocarcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Dedifferentiated Carcinoma +6 • Eligibility: Inclusion Criteria: * Patients with measurable or non-measurable (detectable) recurrent endometrial cancer * Measurable disease will be defined and monitored by RECIST v 1.1. Measurable disease is defined…. Goal: This phase II trial tests whether the combination of nivolumab and ipilimumab is better than nivolumab alone to shrink tumors in patients with deficient mismatch repair system (dMMR) endometrial carcinoma that has come back after a period of time during which the cancer could not be detected (recurrent). Deoxyribonucleic acid (DNA) mismatch repair (MMR) is a system for recognizing and repairing damaged DNA. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Testing the Addition of an Anti-Cancer Drug, Triapine, to the Usual Radiation Therapy for Recurrent Glioblastoma or Astrocytoma is being studied. Conditions: Astrocytoma, IDH-Mutant, Grade 2, Recurrent Adult Diffuse Hemispheric Glioma, H3 G34-Mutant, Recurrent Adult Diffuse Midline Glioma, H3 K27-Mutant +4 • Eligibility: Inclusion Criteria: * Patients must have histologically, molecularly, or cytologically confirmed recurrent astrocytic tumors including: * GBM or variants, IDH-wildtype, grade 2-4 (standard curative measures available or not)…. Goal: This phase I trial tests the safety, side effects, and best dose of triapine in combination with radiation therapy in treating patients with glioblastoma or astrocytoma that has come back after a period of improvement (recurrent). Triapine may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Gene Modified Immune Cells After Conditioning Regimen for the Treatment of Stage IIIC or IV Melanoma or Metastatic Solid Tumors is being studied. Conditions: Metastatic Malignant Solid Neoplasm, Metastatic Melanoma, Pathologic Stage IIIC Cutaneous Melanoma AJCC v8 +14 • Eligibility: Inclusion Criteria: * Histologically confirmed malignancy that is considered surgically incurable with either: * Stage IIIC melanoma including locally relapsed, satellite, in-transit lesions or bulky draining node metastasis…. Goal: This phase I trial studies the side effects and best dose of modified immune cells (IL13Ralpha2 CAR T cells) after a chemotherapy conditioning regimen for the treatment of patients with stage IIIC or IV melanoma or solid tumors that have spread to other places in the body (metastatic). The study agent is called IL13Ralpha2 CAR T cells. Phase/Status/Sponsor: Unknown phase; RECRUITING; Anusha Kalbasi.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

SynKIR-110 for Mesothelin Expressing Ovarian Cancer, Cholangiocarcinoma or Mesothelioma is being studied. Conditions: Ovarian Cancer, Cholangiocarcinoma Recurrent, Mesothelioma, Malignant • Eligibility: Inclusion Criteria: * Pathologically confirmed recurrent or relapsed advanced ovarian cancer, primary peritoneal cancer, fallopian tube cancer, cholangiocarcinoma, or epithelial mesothelioma (pleural or peritoneal) after at least 1…. Goal: This first-in-human (FIH) trial is designed to assess the safety, feasibility, and potential activity of a single intravenous (IV) dose of SynKIR-110 administered to subjects with mesothelin-expressing advanced ovarian cancer, mesothelioma, and cholangiocarcinoma. Phase/Status/Sponsor: Unknown phase; RECRUITING; Verismo Therapeutics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors is being studied. Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer +6 • Eligibility: Inclusion Criteria: 1. Adult participants must be 18 years of age or older 2. Advanced or metastatic solid tumors excluding primary central nervous system (CNS) tumors 3. For…. Goal: The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab. Phase/Status/Sponsor: Unknown phase; RECRUITING; IDEAYA Biosciences.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

PLX038 for Treatment of Metastatic Platinum-resistant Ovarian, Primary Peritoneal, and Fallopian Tube Cancer is being studied. Conditions: Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma +3 • Eligibility: Inclusion Criteria: * Age \>= 18 years NOTE: Because no dosing or adverse event data are currently available on the use of PLX038 in patients \< 18 years…. Goal: This phase II trial tests whether pegylated SN-38 conjugate PLX038 (PLX038) works to shrink tumors in patients with ovarian, primary peritoneal, and fallopian tube cancers that has spread from where it first started (primary site) to other places in the body (metastatic). PLX038 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; RECRUITING; Mayo Clinic.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study Using Hyperpolarized 13C-Pyruvate Magnetic Resonance Spectroscopic Imaging in Patients With Pancreatic Cysts Undergoing Surgical Resection is being studied. Conditions: Pancreatic Cyst • Eligibility: Inclusion Criteria: * Patients ≥ 18 years old. Patients under 18 are excluded due to their potential inability to understand and consent independently to the methods required for…. Goal: To learn if Hyperpolarized C-Pyruvate Magnetic Resonance (HP-MR) Spectroscopic Imaging can help doctors detect low-risk (benign) and high-risk (malignant) cysts. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Global Study of the PETAL Consortium is being studied. Conditions: T-Cell and NK-Cell Neoplasm • Eligibility: Inclusion Criteria: * Untreated, relapsed, or refractory histologically confirmed mature T-cell or NK-cell neoplasm. * All subtypes of PTCL are eligible except for T-cell large granular lymphocytic leukemia,…. Goal: The goal of this observational study is to correlate molecular alterations with outcomes including overall survival (OS), progression-free survival (PFS), response rates for patients with a new diagnosis, primary refractory or relapse, of mature T-cell and NK-cell neoplasms (TNKL). We hypothesize that machine learning can be leveraged to uncover distinct genetic vulnerabilities that underlie treatment response and resistance for patients with TNKL, thus moving towards personalized treatment solutions. Phase/Status/Sponsor: Unknown phase; RECRUITING; Massachusetts General Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of ZW191 in Participants With Solid Tumors is being studied. Conditions: Advanced Solid Tumors • Eligibility: Inclusion Criteria: * Pathologically or cytologically confirmed diagnosis of cancers with evidence of locally advanced (unresectable), recurrent and/or metastatic disease. * Measurable disease per RECIST v1.1. * Eastern…. Goal: The purpose of this study is to find out if ZW191 is safe and can treat participants with advanced cancers, including ovarian, endometrial, and non-small cell lung cancers. Phase/Status/Sponsor: Unknown phase; RECRUITING; Zymeworks BC Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This is a first-in-human study testing VVD-130037 in people with advanced solid tumors, using dose escalation and dose expansion, as a single agent or in combination with docetaxel, paclitaxel, or pembrolizumab. - The trial aims to determine safe and tolerable doses and learn how the drug behaves in the body, while gathering early signals about efficacy. - Eligible participants are adults with metastatic or unresectable solid tumors that progressed after standard therapies, with measurable disease and a good performance status (ECOG 0–1); Part 2 adds specific squamous cancers (e.g., sqNSCLC with or without NRF2/CUL3 mutations, HNSCC, ESCC) with prior platinum therapy and/or immune therapy as applicable. - Key exclusions include certain KEAP1 mutations that are not expected to benefit VVD-130037, unresolved toxicity, seizure risk or CNS metastases, uncontrolled hypertension, significant heart problems, prior severe immunotherapy toxicity, and active pneumonitis or ILD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a first-in-human study of VVD-159642, a RAS-PI3Kα inhibitor, in adults with advanced solid tumors. It aims to evaluate safety and tolerability, plus how the drug behaves in the body (PK/PD), and to see any early anti-tumor activity, both by itself and in combination with sotorasib or trametinib. Eligible participants include people with pancreatic ductal adenocarcinoma, colorectal cancer, non-small cell lung cancer, or any solid tumor with RAS alterations (KRAS, NRAS, HRAS), or with EGFR alterations or HER2 overexpression. Key exclusions include active CNS cancers, significant cardiac disease, uncontrolled hypertension, inflammatory bowel disease or malabsorption issues, and active hepatitis B or C infections.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors is being studied. Conditions: Locally Advanced or Metastatic Solid Tumors, Colorectal Cancer, Gastric Cancer +1 • Eligibility: 1. Willing to sign the informed consent form and follow the requirements specified in the protocol. 2. Life expectancy ≥ 3 months. 3. Tumor specimen available for CDH17…. Goal: This is an open-label, multi-center, phase I study to evaluate the safety, tolerability, efficacy, and pharmacokinetics of MRG007 (ARR-217) in patients with unresectable locally advanced or metastatic solid tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; ArriVent BioPharma, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests whether ide-cel (bb2121) CAR T-cell therapy for multiple myeloma can be made from a patient’s T cells after a hematopoietic cell transplant, and whether the quality of those T cells affects how well ide-cel prevents the cancer from returning. - It includes two groups of adults with relapsed or refractory multiple myeloma who have had at least four prior therapies and a transplant: Cohort 1 is autoHCT within 2–6 months, Cohort 2 is after alloHCT with minimal residual disease. - The trial aims to learn if the cell source and manufacturing quality influence ide-cel’s effectiveness and safety after transplantation. - The study is currently recruiting. - Key exclusions include active infection, significant organ dysfunction, prior organ transplant requiring systemic immunosuppression, and pregnancy or breastfeeding, among other serious conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) Telisotuzumab Adizutecan Compared to Standard of Care in Adult Participants With Locally Advanced or Metastatic EGFR-Mutated Non-Squamous Non-Small Cell Lung Cancer is being studied. Conditions: Non-Small Cell Lung Cancer • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed diagnosis of locally advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) with documented EGFR Exon 19 deletion or Exon21 L858R…. Goal: Non-small cell lung cancer (NSCLC) is a common type of lung cancer where abnormal cells in the lungs grow out of control. The purpose of this study is to assess adverse events and change in disease activity of telisotuzumab adizutecan compared to standard of care (SOC). Phase/Status/Sponsor: Unknown phase; RECRUITING; AbbVie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests whether iberdomide maintenance is better or similar to lenalidomide maintenance after autologous stem cell transplantation in people with newly diagnosed multiple myeloma. - It is for adults with symptomatic multiple myeloma who have completed induction therapy that included a proteasome inhibitor and an IMiD, and who have had one or two autologous stem cell transplants within 12 months (single) or 15 months (tandem) from the start of induction, achieving at least a partial response. - The trial aims to learn which maintenance approach helps keep the cancer under control after transplant and how tolerable the treatments are. - Key exclusions include progressive disease after transplant, smoldering or nonsecretory myeloma, CNS involvement, and a prior history of other cancers unless disease-free for at least 5 years.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests whether a limited partial pleurectomy with decortication can help relieve symptoms in people with pleural mesothelioma that cannot be fully removed. It is for adults with epithelioid pleural mesothelioma affecting one side of the chest and classified as unresectable or borderline resectable after initial therapy. Researchers will look at symptoms, quality of life, complications after surgery, time to starting any additional treatment, and overall survival over about two years. Key exclusions include biphasic or sarcomatoid mesothelioma, cancer that has spread beyond the chest, progression during induction therapy, poor lung function, use of other investigational drugs, or uncontrolled illness.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Evaluate Adverse Events and Efficacy of Intravenous (IV) Telisotuzumab Adizutecan in Combination With a PD-1 Immune Checkpoint Inhibitor in Adult Participants With Advanced or Metastatic Non-Squamous NSCLC With No Prior Treatment for Advanced Disease, and No Actionable Genomic Alterations is being studied. Conditions: Non Small Cell Lung Carcinoma • Eligibility: Inclusion Criteria: * Must have histologically documented non-squamous (NSq) non small cell lung carcinoma (NSCLC) that is locally advanced or metastatic will be enrolled into the study. *…. Goal: Non small cell lung carcinoma (NSCLC) is the most frequently occurring histologic subtype of lung cancer and is the leading cause of cancer-related deaths worldwide. The purpose of this study is to assess adverse events and change in disease activity when Telisotuzumab Adizutecan (ABBV-400) is given in combination with a programmed cell death receptor 1 (PD1) immune checkpoint inhibitor to adult participants to treat NSCLC. Phase/Status/Sponsor: Unknown phase; RECRUITING; AbbVie.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II Study of Axicabtagene Ciloleucel, an Anti-CD19 Chimeric Antigen Receptor (CAR) Tcell Therapy, in Combination With Radiotherapy (RT) in Relapsed/Refractory Follicular Lymphoma is being studied. Conditions: Follicular Lymphoma • Eligibility: Inclusion Criteria: Eligible subjects will be considered for inclusion if they meet all of the following criteria: * Men and women 18 years of age or older *…. Goal: To learn about the safety of a drug called axicabtagene ciloleucel given in combination with radiation therapy to patients with relapsed/refractory FL. Phase/Status/Sponsor: Unknown phase; RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of ASP2138 Given by Itself or Given With Other Cancer Treatments in Adults With Stomach Cancer, Gastroesophageal Junction Cancer, or Pancreatic Cancer is being studied. Conditions: Gastric Adenocarcinoma, Gastroesophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma • Eligibility: Inclusion Criteria: * Participant is considered an adult according to local regulation at the time of signing the informed consent form (ICF). * Female participant is not pregnant,…. Goal: Claudin 18.2 protein, or CLDN18.2 is a protein found on cells in the digestive system. It is also found on some tumors. Phase/Status/Sponsor: Unknown phase; RECRUITING; Astellas Pharma Global Development, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy of the Combination of Trimipramine and Atezolizumab With Bevacizumab in Patients With Recurrent Glioblastoma: a Phase 2 Trial is being studied. Conditions: Glioblastoma, Recurrence Tumor • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed glioblastoma, according to World Health Organization \[WHO\] 2021 with unequivocal first progression after standard (6 weeks radiotherapy \[RT\]) with concurrent \&…. Goal: This is a multicentric phase II open-label clinical trial aiming to assess the efficacy of the combination of trimipramine and atezolizumab with bevacizumab in patients with recurrent glioblastoma. Eligible patients will be assigned to two cohorts depending on whether there is a medical indication for a neurosurgical resection from first recurrent tumor or not. Phase/Status/Sponsor: Unknown phase; RECRUITING; Centre Hospitalier Universitaire Vaudois.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study to Evaluate INCB123667 Versus Investigator's Choice of Chemotherapy in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression is being studied. Conditions: Ovarian Cancer • Eligibility: Inclusion Criteria: * Histological diagnosis of high-grade serous epithelial ovarian, fallopian tube, or primary peritoneal cancer. * Have platinum-resistant disease. * Participants who have only had 1 line…. Goal: The purpose of this study is to evaluate INCB123667 versus investigator's choice of chemotherapy in participants with platinum-resistant ovarian cancer with cyclin E1 overexpression. Phase/Status/Sponsor: Unknown phase; RECRUITING; Incyte Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

N-803 and PD-L1 t-haNK Combined With Bevacizumab for Recurrent or Progressive Glioblastoma is being studied. Conditions: Glioblastoma • Eligibility: Phase 2 Inclusion Criteria: 1. Age ≥ 18 years. 2. Able to understand and provide a signed informed consent that fulfills the relevant IRB or IEC guidelines. 3.…. Goal: This study consists of 2 portions. The phase 2 portion is an open-label, single-arm study to evaluate the safety and efficacy of NAI, PD-L1 t-haNK, and bevacizumab combination therapy in participants with recurrent or progressive GBM. Phase/Status/Sponsor: Unknown phase; RECRUITING; ImmunityBio, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of LY4337713 in Participants With FAP-Positive Solid Tumors is being studied. Conditions: Ovarian Neoplasms, Breast Neoplasms, Pancreatic Intraductal Neoplasms +4 • Eligibility: Inclusion Criteria: * Must have clinical or imaging evidence of fibroblast activation protein (FAP) expression per local assessment * Must have histologically or cytologically confirmed diagnosis of one…. Goal: This is a study of LY4337713 in participants with certain types of cancer that is advanced or has spread. Participants must have cancer with high levels of a protein called fibroblast activation protein (FAP). Phase/Status/Sponsor: Unknown phase; RECRUITING; Eli Lilly and Company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial compares rilvegostomig plus gemcitabine and cisplatin versus durvalumab plus gemcitabine and cisplatin as first-line treatment for advanced biliary tract cancer. - It is for adults with unresectable locally advanced or metastatic BTC, including intrahepatic or extra-hepatic cholangiocarcinoma and gallbladder cancer, who have not yet received systemic therapy for advanced disease and have measurable disease with good performance status. - The study aims to learn which regimen provides better efficacy and acceptable safety when used at the start of treatment. - Key exclusions include ampullary cancer, prior systemic therapy for unresectable or metastatic BTC, prior exposure to immune-targeting therapies, active autoimmune disease requiring steroids, and certain interstitial lung disease or serious skin conditions. - Sponsor: AstraZeneca; Status: Recruiting; Phase: Unknown.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery is being studied. Conditions: Mucosal Melanoma, PD-L1 Positive • Eligibility: Inclusion Criteria: 1. Sign a written informed consent form (Informed Consent, ICF) and be able to comply with the visit schedule and related procedures outlined in the protocol.…. Goal: Melanoma has emerged as the fastest-growing malignancy in recent years, with incidence and mortality rates among both men and women in East Asian countries exceeding the Asian average. China ranks fifth among East Asian nations in melanoma incidence. Phase/Status/Sponsor: Unknown phase; RECRUITING; The First Hospital of Jilin University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of Brentuximab Vedotin With Doxorubicin, Vinblastine and Dacarbazine in Adults With Hodgkin Lymphoma in India is being studied. Conditions: Hodgkin Lymphoma • Eligibility: Inclusion Criteria 1. Treatment-naïve, Hodgkin lymphoma (HL) participants with Ann Arbor Stage 3 or 4 disease. Note: Participants must have histologically confirmed classical HL according to the current…. Goal: The main aim of this study is to check how safe brentuximab vedotin is in adults with untreated Hodgkin Lymphoma (HL) when given together with doxorubicin (Adriamycin), vinblastine and dacarbazine therapy ('AVD'). Another aim is to learn how well treatment of brentuximab vedotin plus AVD works. Phase/Status/Sponsor: Unknown phase; RECRUITING; Takeda.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study of Pembrolizumab (MK-3475) Versus Chemotherapy in Chinese Participants With Stage IV Colorectal Cancer (MK-3475-C66) is being studied. Conditions: Colorectal Neoplasms • Eligibility: The main inclusion and exclusion criteria include but are not limited to the following: Inclusion Criteria: Inclusion Criteria include, but are not limited to: * Has a histologically…. Goal: In this study, Chinese participants with MSI-H or dMMR advanced colorectal cancer will be assigned to receive either pembrolizumab or the Investigator's choice of 1 of 6 standard of care (SOC) chemotherapy regimens for treatment. There is no hypothesis testing for this study. Phase/Status/Sponsor: Unknown phase; RECRUITING; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests INBRX-109, a DR5-targeting antibody, in people with locally advanced or metastatic solid tumors, including sarcomas. It is a first-in-human, open-label, three-part phase 1 study to assess safety and to determine a dose for future use. Eligible participants include people aged 12-84 with Ewing sarcoma and 18-84 with other tumors, all with measurable disease; there are expansion groups for Ewing sarcoma with the classical fusion and for colorectal adenocarcinoma with limited prior therapy. Exclusions include prior DR5 agonist treatment, recent anticancer therapy, active liver disease, and active CNS tumors or HIV/HBV/HCV infection. The study is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Efficacy and Safety of TYRA-300 in Participants With FGFR3 Altered Low Grade, Intermediate Risk Non-Muscle Invasive Bladder Cancer is being studied. Conditions: Low-grade NMIBC, FGFR Gene Amplification, FGFR Gene Alterations +3 • Eligibility: Inclusion Criteria: * Participants age 18 and over of informed consent and willing and able to comply with all requires study procedures * Able to understand and given…. Goal: Phase 2 Study of TYRA-300 in FGFR3 Altered Low Grade, Intermediate Risk NMIBC Phase/Status/Sponsor: Unknown phase; RECRUITING; Tyra Biosciences, Inc.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests a drug called JNJ-79635322 to see if it helps people with relapsed or refractory multiple myeloma. It is for adults who have had at least three prior therapies, including a proteasome inhibitor, an immunomodulatory drug (IMiD), and an anti-CD38 antibody, and who have measurable disease. Researchers want to learn how well the drug works and how safe it is in this group. Key exclusions include allergies to the drug’s ingredients, major surgery within two weeks before dosing, active CNS involvement or leptomeningeal disease, and a second cancer that could interfere with results.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests the drug JNJ-88549968 for people with CALR-mutated essential thrombocythemia (ET) or myelofibrosis (MF). - It aims to find a safe dose and the best dosing schedule (the RP2D) in a dose-escalation part, and then evaluate safety at that dose in an expansion part. - In US sites, the study also looks at using the drug as a stand-alone treatment and in combination with ruxolitinib or momelotinib for MF. - Eligible participants are adults (18+) with CALR mutations and ECOG 0–2; key exclusions include allergies to study drug ingredients, certain recent or active cancers (with exceptions), prior organ transplant, specific stem cell transplant history, and recent major cardiovascular disease.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests INCA035784 to see if it is safe and tolerable in adults with myeloproliferative neoplasms (MPNs). - It includes participants with CALR exon-9 mutations and a confirmed MPN, such as high-risk myelofibrosis after prior treatment or high-risk essential thrombocythemia. - The trial has dose-escalation and dose-expansion parts and requires good performance status (ECOG 0-1 for the dose-escalation phase and 0-2 for the expansion phase) with certain blood test criteria. - Key exclusions include recent major bleeding or thrombosis, active or high-risk HBV/HCV/HIV infections, recent invasive cancer (with some exceptions), and pregnancy. - The study is currently recruiting and is sponsored by Incyte Corporation.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II Study of Pemigatinib Plus Durvalumab in Previously Treated Advanced Intrahepatic Cholangiocarcinoma Patients With FGFR-2 Fusion or Rearrangement is being studied. Conditions: Intrahepatic Cholangiocarcinoma, FGFR2 Gene Rearrangement, FGFR2 Gene Mutation • Eligibility: Inclusion Criteria: 1. Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent…. Goal: This is a single arm phase II study of pemigatinib and durvalumab combination in patients with FGFR-2 fusion or rearrangement positive intrahepatic cholangiocarcinoma. Each cycle will be 3 weeks. Phase/Status/Sponsor: Unknown phase; RECRUITING; Mehmet Akce.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of 14C-Bleximenib (Radiolabeled) in Participants With Acute Leukemia is being studied. Conditions: Acute Lymphoblastic Leukemia, Acute Leukemias, Acute Myeloid Leukemia • Eligibility: Inclusion criteria: * Body weight greater than or equal to (\>=) 40 kilograms (kg) * Relapsed or refractory (R/R) acute leukemia harboring histone-lysine N-methyltransferase 2A (KMT2A), nucleophosmin 1…. Goal: The purpose of this study is to assess how the body absorbs, breaks down (metabolism), and removes (excretes) radiolabeled bleximenib (a drug molecule that has been chemically bonded with a radioactive isotope which emits radiation making it easier to track in the body) in participants with acute leukemia (highly aggressive blood cancer typically characterized by large numbers of immature white blood cells in the bone marrow). Phase/Status/Sponsor: Unknown phase; RECRUITING; Janssen Research & Development, LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests amivantamab plus FOLFIRI versus cetuximab/bevacizumab plus FOLFIRI in people with KRAS/NRAS and BRAF wild-type colorectal cancer who have previously received chemotherapy. - It aims to learn whether the amivantamab combination improves progression-free survival and overall survival compared with the cetuximab/bevacizumab combination. - Eligible participants have recurrent, unresectable, or metastatic colorectal cancer with confirmed KRAS/NRAS and BRAF wild-type status, have had at least one prior systemic therapy for metastatic disease, and have ECOG 0–1. - Key exclusions include preexisting interstitial lung disease/pneumonitis, allergies to study drugs, prior exposure to irinotecan or EGFR/MET inhibitors, HER2-positive tumors, or another active malignancy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Chemoradiotherapy Versus Chemotherapy for Elderly and Frail GBM Patients is being studied. Conditions: Glioblastoma Multiforme • Eligibility: Inclusion Criteria: 1. Newly-diagnosed, histologically proven, intracranial glioblastoma with maximal safe resection. Biopsy alone is expected if resection is not possible. MGMT promoter methylation status must be tested…. Goal: Currently, the optimal treatment regimen for elderly Glioblastoma (GBM) patients with poor performance status (PS) is unknown. Based on data for elderly GBM patients and the limited data for patients with poor PS, hypofractionated RT or a short course of Temozolomide (TMZ) may provide survival benefit without the added toxicity and inconvenience of a more protracted treatment regimen. Phase/Status/Sponsor: Unknown phase; RECRUITING; AHS Cancer Control Alberta.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Sacituzumab Tirumotecan (MK-2870) Plus Pembrolizumab Versus TPC in TNBC Who Did Not Achieve pCR (MK-2870-012) is being studied. Conditions: Triple-Negative Breast Cancer • Eligibility: Inclusion Criteria: * Has centrally confirmed TNBC, as defined by the most recent American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) guidelines * Has no evidence of…. Goal: This is a randomized, open-label study comparing the efficacy and safety of adjuvant sacituzumab tirumotecan (MK-2870) in combination with pembrolizumab compared to treatment of physician's choice (TPC) in participants with triple-negative breast cancer (TNBC) who received neoadjuvant therapy and did not achieve a pathological complete response (pCR) at surgery. The primary objective is to compare sacituzumab tirumotecan plus pembrolizumab to TPC (pembrolizumab or pembrolizumab plus capecitabine) with respect to invasive disease-free survival (iDFS) per investigator assessment. Phase/Status/Sponsor: Unknown phase; RECRUITING; Merck Sharp & Dohme LLC.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma is being studied. Conditions: Lymphoma • Eligibility: Inclusion Criteria * Participant must be 18 years or older at the time of signing the informed consent form (ICF). * Histologically confirmed primary central nervous system (CNS)…. Goal: The purpose of this study is to evaluate the safety and efficacy of lisocabtagene maraleucel (Breyanzi/liso-cel/BMS-986387) in adults as first-line treatment in transplant-ineligible Primary Central Nervous System Lymphoma (PCNSL). Phase/Status/Sponsor: Unknown phase; RECRUITING; Juno Therapeutics, Inc., a Bristol-Myers Squibb Company.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This open, multicenter trial tests SHR-A1811 combined with chemotherapy and/or immunotherapy in adults with HER2-positive advanced or metastatic gastric or gastroesophageal junction cancer. It has two parts: Phase Ib to assess safety, tolerability, how the drug behaves in the body, immune response, and early anti-tumor signals; Phase II to assess how well the combination works and its safety. Eligible participants are adults aged 18 to 75 with unresectable or metastatic HER2-positive gastric/GEJ adenocarcinoma; Phase Ib includes people who have had prior therapy or none, while Phase II is for previously untreated patients. Key exclusions include symptomatic ascites or effusions needing treatment, active autoimmune disease or interstitial pneumonia, severe infection, recent major surgery, active tuberculosis in the past year, and serious cardiovascular or cerebrovascular disease. The trial is currently recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

LY900023 is a master protocol that covers several cancer drug studies for children and young adults, with new studies added as new drugs emerge. Participants must have measurable or evaluable cancer by RECIST 1.1 and a Lansky score under 16 or Karnofsky score 16 or higher, with a minimum position of 50, and they must have stopped prior cancer treatments for at least 7 days and recovered. The trial aims to learn how safe and effective the drugs are and how long any benefits last, all under a shared protocol. Key exclusions include severe or uncontrolled illnesses, active infections, prior allogeneic transplant, certain invasive procedures, and pregnancy or breastfeeding; women of childbearing potential must have a negative pregnancy test and use contraception during and for a period after the study.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This is a multicenter screening study to find out how often the KIT D816V mutation occurs in people with suspected clonal mast cell disease. It has three cohorts: Cohort 1 includes people with suspected systemic mast cell activation disease; Cohort 2 includes people with hypermobility-related conditions, POTS, or early osteoporosis/osteopenia; Cohort 3 includes people with certain myeloid disorders per WHO criteria. The study aims to learn the prevalence of the KIT D816V mutation in these groups to inform diagnosis and future research. Exclusions include prior diagnosis of KIT-mutated monoclonal mast cell activation syndrome, cutaneous mastocytosis only, any systemic mastocytosis subtype, or mast cell sarcoma; Cohort 2 also excludes osteoporosis/osteopenia due to other known causes.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This multicenter, open-label, single-group trial tests photodynamic therapy using Cosiporfin Sodium together with gemcitabine and cisplatin (GC) for people with locally advanced or recurrent metastatic extrahepatic cholangiocarcinoma that cannot be operated on. - It aims to preliminarily measure efficacy, focusing on the 6-month overall survival rate, and to assess safety and tolerability of the PDT plus GC treatment in patients with biliary obstruction. - Eligible participants are adults with histologically confirmed disease, inoperable or unwilling to have surgery, with biliary obstruction and at least one measurable lesion outside the bile ducts, plus good performance status and adequate organ function. - Key exclusions include ampullary cancer, brain metastases, major liver tumor burden (>50%), prior exposure to photosensitizers or PDT, prior systemic therapy in the recurrent/metastatic setting, unremovable biliary stents, active infections, and other conditions that could interfere with treatment.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Lu-TARGO trial tests LNTH-2403, a 177Lu-labeled radiopharmaceutical, for people with relapsed or refractory osteosarcoma. It is a non-randomized, open-label study that will measure how the drug distributes in the body (dosimetry), test increasing dose levels, and then expand a cohort to gather more data. Eligible participants include those with relapsed/refractory osteosarcoma who have progressed after at least one chemotherapy course, with age groups starting at 18 years (Phase 1) and then 12 years or older in later cohorts and Phase 2, and who meet imaging and performance criteria. Key exclusions include allergy to LNTH-2403 or its components, active infection or significant other illnesses, ongoing anti-cancer therapy, pregnancy or breastfeeding, HIV, active liver disease, recent major surgery, or inability to comply with study procedures.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The SPEARHEAD-3 Pediatric Study is testing a treatment called afamitresgene autoleucel in children and teens with certain advanced cancers. It includes patients whose tumors express MAGE-A4 and who are HLA-A*02 positive, across cancers such as synovial sarcoma, MPNST, neuroblastoma, and osteosarcoma (ages 2-17 for synovial sarcoma; 2-21 for the other cancers). The study aims to assess safety and whether the treatment helps, after prior chemotherapy and with measurable disease before treatment. Key exclusions include HLA-A*02:05 positivity or similar A*02 variants, autoimmune disease, CNS metastases, active infections (HIV, HBV, HCV), pregnancy, significant cardiovascular disease, or another cancer not in remission.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Bipolar Androgen Therapy (BAT) and Radium-223 (RAD) in Metastatic Castration-resistant Prostate Cancer (mCRPC) is being studied. Conditions: Prostate Adenocarcinoma, Metastatic Prostate Adenocarcinoma, Castration-resistant • Eligibility: Inclusion Criteria: * Histologically documented adenocarcinoma of the prostate confirmed by pathology report from prostate biopsy or a radical prostatectomy specimen. If prostatic tumor is of mixed histology,…. Goal: This is a single-arm, multicenter open label, international, phase II study of Bipolar Androgen Therapy (BAT) plus Radium-223 (RAD) in men with metastatic castration-resistant prostate cancer (mCRPC). Men with mCRPC with progressive disease (radiographically and/or biochemically) who have been treated with gonadotropin-releasing hormone (GnRH)-analogue (LHRH agonists/antagonists) continuously or bilateral orchidectomy will be enrolled in this study. Phase/Status/Sponsor: Unknown phase; RECRUITING; Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests whether vicadrostat taken with empagliflozin can reduce cardiovascular risk in adults with type 2 diabetes, high blood pressure, and cardiovascular disease. - Participants must have those conditions and no history of heart failure. - It compares vicadrostat plus empagliflozin to a placebo plus empagliflozin, with once-daily tablets for about 2.5 to 4 years. - Key exclusions include history of heart failure, certain heart rhythm problems, and use of specific heart medicines such as mineralocorticoid receptor antagonists or potassium-sparing diuretics.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests APG-115, an oral mdm2 inhibitor, in people with BAP1 Cancer Syndrome who also have early-stage mesothelioma. - It is for adults 18 and older who have a germline BAP1 mutation and subclinical/early-stage mesothelioma that does not yet require standard treatment. - The trial aims to determine whether APG-115 can stabilize or improve the disease, using pre- and post-treatment biopsies and imaging to assess response, with treatment given in 21-day cycles for up to 16 cycles. - The study is not yet recruiting. - Exclusions include cancers requiring frontline therapy, significant cardiovascular disease, certain drug interactions, active viral infections (HBV/HCV/HIV), pregnancy, and other unstable medical conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests pacritinib, a multi-kinase inhibitor that targets CSF1R, IRAK1, JAK2, and FLT3, in adults and youths aged 12 years and older with myelodysplastic syndromes (MDS) or MDS/MPN. - It has two parts: Phase I in 12–17 year-olds to find a safe dose, and Phase II in adults 18+ to see if pacritinib helps, measured by overall response rate in two risk-based groups. - Eligible participants must have confirmed MDS or MDS/MPN and disease status defined by prior therapy resistance or ineligibility, depending on risk. - Key exclusions include active severe bleeding, uncontrolled infection, certain heart conditions or QT prolongation risk, pregnancy, and certain drug interactions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Multicomponent Care for Aromatase Inhibitor-Related Musculoskeletal Symptoms is being studied. Conditions: Breast Neoplasms, Musculoskeletal Pain, Arthralgia +3 • Eligibility: Inclusion Criteria: 1. Pathologically confirmed hormone receptor-positive (HR+) breast cancer. 2. Aged 18 years or older. 3. Currently receiving aromatase inhibitor therapy (e.g., anastrozole, letrozole, or exemestane) for…. Goal: Breast cancer patients who receive endocrine therapy particularly aromatase inhibitors often experience aromatase inhibitors associated symptoms (AIMSS) such as joint and muscle pain along with stiffness and fatigue that can disrupt with daily activities and lead some patients to stop treatment early. A structured intervention program named AIMSS-CARE (Aromatase Inhibitor-associated Musculoskeletal Symptoms-Comprehensive Adapted Rehabilitation Evaluation) developed in China that combines exercise, education, symptom monitoring, and follow-up has been shown to reduce these symptoms and improve treatment adherence. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Addis Ababa University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

OPTIMUM-PCa: MRI- and PHI-Guided Prostate Cancer Diagnosis is being studied. Conditions: Prostate Cancer (Diagnosis), Prostate Cancer • Eligibility: Inclusion Criteria: * Male, aged 20 years or older * Serum PSA ≥3.0 ng/mL and ≤20.0 ng/mL and/or abnormal digital rectal -examination * Biopsy-naïve * Clinical stage ≤T2…. Goal: Prostate cancer diagnosis based on systematic or MRI-targeted biopsy is associated with substantial overdiagnosis and unnecessary invasive procedures. Although multiparametric MRI improves detection of clinically significant prostate cancer, optimal criteria for biopsy omission-particularly in men with equivocal MRI findings-remain uncertain. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; In Gab Jeong, MD.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The study tests a 3D biliary tract reconstruction tool and an AI algorithm to help endoscopists perform ERCP by creating 3D models from MRCP and CT scans. - It is for adults with biliary strictures who are treated with ERCP at Saint Antoine Hospital or Henri Mondor Hospital. - The study is retrospective and uses imaging data collected during routine care to develop and validate the software. - The goal is to see if the 3D models improve visualization and navigation during ERCP, with performance assessed by image-quality metrics and localization error, and without changing patient management. - Exclusion: patients who do not consent to reuse their data for research.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests a cell therapy called B7-H3.CD28Z.CART (B7-H3 CAR T cells) for children and young adults with recurrent or progressive brain tumors. Participants receive pre-treatment chemotherapy (fludarabine and cyclophosphamide) to prepare the body before the CAR T cells are given. The trial uses a dose-escalation design to find a safe and potentially effective dose and to study two risk groups (standard and high risk). It aims to learn about safety and whether the therapy helps tumors that express B7-H3 in ages 2 to 21 with certain CNS embryonal tumors or recurrent/progressive ependymoma. The study is not yet recruiting, and key exclusions include bulky tumors, brain herniation, active infections, or prior B7-H3 cellular therapies.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

The Use of Cultured Epithelial Autografts (CEA) or Cultured Dermal Epidermal Autografts (CDEA) in Severely Burned Patients is being studied. Conditions: Burn Degree Second, Burn Degree Third, Skin Transplantation +1 • Eligibility: Inclusion Criteria: * Patients who have undergone treatment at the three Swiss burn centres and received grafts utilizing CEA since the introduction of the CEA technique in Switzerland…. Goal: The Swisskera project is a multicenter follow-up study at the three Swiss burn centers evaluating long-term outcomes after burn wound coverage with lab-grown epithelial grafts, specifically cultured epithelial autograft (CEA) and, where applicable, cultured dermal-epidermal autograft (CDEA). Patients who received CEA/CDEA between 1985 and 2023 will be invited for a study visit , using available clinical records and standardized long-term scar and skin assessments. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; University Children's Hospital, Zurich.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Safety, Pharmacokinetics (PK), and Efficacy of ONC-783 in Advanced Solid Tumors is being studied. Conditions: Advanced Solid Tumor • Eligibility: Inclusion Criteria: * Age ≥ 18 yrs old. * Male or Female * Must have ECOG score ≤ 1. The body weight should be ≥40 kg. The life…. Goal: ONC-783-001 is a Phase I open label, dose-escalation study for evaluating the safety, pharmacokinetics (PK) and efficacy of ONC-783 as a single agent in patients with advanced/metastatic solid tumors, focusing on colorectal cancer, ovarian cancer, pancreatic cancer, or breast cancer. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; OncoC4, Inc..

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- The trial tests a topical spray containing superoxide dismutase (SOD) to help prevent radiation dermatitis. - It is for adults with non-metastatic head and neck cancer who are planned to receive high‑dose radiotherapy, either as the main treatment or after surgery. - Researchers want to learn whether the SOD spray reduces how often and how severe skin damage from radiation is, when it starts, and how it affects symptoms, quality of life, treatment interruptions, and safety. - Key exclusions include poor overall health or skin problems in the treatment area, allergies to trolamine or fullerene, inflammatory or connective tissue skin disorders, and a history of head and neck radiotherapy.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Neoadjuvant Complete Response Customized Treatment Approach for Definitive Management of Breast Cancer is being studied. Conditions: Breast Cancer, HER2-positive Breast Cancer, Triple Negative Breast Cancer • Eligibility: Inclusion Criteria: 1. Provision of signed and dated informed consent form 2. Stated willingness to comply with all study procedures and availability for the duration of the study…. Goal: This study will evaluate the efficacy and non-inferiority of a non-surgical approach for the treatment of patients with locally advanced breast cancer. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Ohio State University Comprehensive Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

ONT01 and Gemcitabine/Nab-paclitaxel as Second Line Therapy for Metastatic Pancreatic Ductal Adenocarcinoma is being studied. Conditions: Metastatic Pancreatic Ductal Adenocarcinoma • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the pancreas. * Measurable or evaluable disease per RECIST 1.1. * Previously treated with first-line systemic therapy for unresectable/advanced…. Goal: The investigators hypothesize that CD11b agonism reprograms the tumor microenvironment (TME) to overcome resistance to checkpoint immunotherapy in pancreatic ductal adenocarcinoma (PDAC). Therefore, the investigators propose an open label phase I/II clinical trial of ONT01 with gemcitabine and nab-paclitaxel in unresectable pancreatic ductal adenocarcinoma prior to future studies incorporating anti-PD1 checkpoint immunotherapy. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; Washington University School of Medicine.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Reproductive Health in Breast Cancer Survivor is being studied. Conditions: Breast Cancer • Eligibility: Exposed cohort (Breast cancer patient) Inclusion Criteria: * Patients aged between 18 and 50 at the time of diagnosis of breast cancer * Diagnosed with stage 1 to…. Goal: With the age of first pregnancy increasing (average age of mother at childbirth: 31.0 in 2022), and the incidence of breast cancer increasing in young women (+2.1% per year according to some registries, more and more women will develop breast cancer before they have a child. FP must be offered to all women under 40 who are going to receive potentially gonadotoxic treatment (French bioethics law of 06/08/04, revised on 07/07/2011). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Institut Cancerologie de l'Ouest.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests Pedmark sodium thiosulfate to protect against cisplatin-related hearing loss. - It is for adults with cancer who have not been treated yet and are going to receive a cisplatin-based chemotherapy regimen. - The study aims to learn whether sodium thiosulfate is safe and effective at reducing hearing impairment in adults, an use already shown in children but less studied in adults. - Key exclusions include prior cisplatin exposure, planned head or neck radiation, pregnancy or breastfeeding, ongoing ototoxic medications, and certain electrolyte problems.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Bevacizumab in Ovarian Cancer Patients With Disease at Second-Look Surgery is being studied. Conditions: Malignant Neoplasms of Female Genital Organs, Ovarian Cancer, Fallopian Tube Cancer +1 • Eligibility: Inclusion Criteria: 1. Signed written Informed Consent (in participant's preferred language or short form, per SOP04). 2. Age\>/= 18 years of age or older. 3. Histologically confirmed Stage…. Goal: The goal of this clinical research study is to learn if Avastin (bevacizumab) can help to control ovarian, fallopian, or primary peritoneal cancer that has been found during second-look surgery. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Continuous Monitoring of Prostate Position During Radiotherapy is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: * Patients undergoing definitive external beam radiotherapy; * Histological proven prostate adenocarcinoma * Prostate Specific Antigen (PSA),within 3 months prior to enrolment * Patient must be…. Goal: This study is investigating measurement of prostate motion during radiotherapy using the implanted gold markers. If motion is greater than 3mm then the beam will be stopped and position corrected (gating). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Royal North Shore Hospital.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP) is being studied. Conditions: Glioblastoma, Glioblastoma, WHO Grade IV • Eligibility: Inclusion Criteria: * Histologic confirmation of glioblastoma, WHO Grade IV (GBM variants are allowed; Lower grade gliomas that have been transformed to GBM will be considered newly diagnosed…. Goal: Glioblastoma multiforme (GBM) is the most common and deadliest primary malignant neoplasm of the central nervous system in adults. Despite an aggressive multimodality treatment approach including surgery, radiation therapy and chemotherapy, overall survival remains poor. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; University of Florida.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests adding elimusertib (BAY 1895344) to standard chemotherapy with cisplatin, or cisplatin plus gemcitabine, for adults with advanced solid tumors, including urothelial cancer. It is a dose-escalation phase I trial to find the safest and most effective dose and to learn how the combination behaves in the body. The trial will assess safety and tolerability, identify the maximum tolerated dose, and collect pharmacokinetics and early signs of activity, with a focus on urothelial cancer in the triplet arm. Eligible participants are adults 18 or older with measurable advanced disease for which cisplatin-based therapy is suitable; key exclusions include pregnancy, life expectancy under 6 weeks, uncontrolled illness, recent chemotherapy or radiotherapy, and certain drug interactions or prior ATR inhibitors. The study is currently active but not recruiting.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study to Determine Whether Chemotherapy and Atezolizumab is Better Than Chemotherapy, Bevacizumab and Atezolizumab in Patients With Advanced Liver Cancer is being studied. Conditions: Combined Hepatocellular Carcinoma and Cholangiocarcinoma, Stage III Liver Cancer, Stage IV Liver Cancer • Eligibility: Inclusion Criteria: * Patient must be \>= 18 years of age * Patient must have a histologically confirmed diagnosis of combined hepatocellular carcinoma-cholangiocarcinoma (cHCC-CC) at the local laboratory…. Goal: This phase II trial compares the effect of adding bevacizumab and atezolizumab to gemcitabine and cisplatin (chemotherapy) versus chemotherapy and atezolizumab in treating patients with liver cancer that cannot be removed by surgery (unresectable) or that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Atezolizumab, Obinutuzumab, and Venetoclax in Treating Patients With Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, or Relapsed or Refractory Richter Syndrome is being studied. Conditions: Chronic Lymphocytic Leukemia, Recurrent Transformed Chronic Lymphocytic Leukemia, Refractory Transformed Chronic Lymphocytic Leukemia +2 • Eligibility: Inclusion: 1. Patients will have a diagnosis of CLL or SLL or RTand are: a) Cohort 1: Patients with treatment naïve CLL/SLL who meet IWCLL criteria for treatment…. Goal: This phase II trial studies how well atezolizumab, obinutuzumab, and venetoclax work in treating patients with chronic lymphocytic leukemia or small lymphocytic lymphoma or Richter syndrome that has come back (recurrent) or does not respond to treatment (refractory). Immunotherapy with monoclonal antibodies, such as atezolizumab and obinutuzumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This trial tests a combination of cisplatin, docetaxel, and pembrolizumab (PCD) in people with newly diagnosed stage II–III laryngeal cancer. It aims to measure the clinical benefit after 2 cycles and the pathologic complete response after 4 cycles of PCD. Secondary goals include safety, the 2-year rate of preserving the larynx, relapse-free and overall survival, and patient-reported and swallowing outcomes. Eligible participants are untreated, stage II–III laryngeal cancer patients; key exclusions include prior anti-PD-1/PD-L1 therapy, active autoimmune disease needing systemic treatment, active infections or immunodeficiency, HIV or hepatitis B/C, pregnancy, and recent systemic cancer therapy or certain live vaccines.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) is being studied. Conditions: Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Non-Small Cell Cancer AJCC v7 • Eligibility: Inclusion Criteria: * Age \>= 18 years * Patients must have undergone complete surgical resection of their stage IB (\>= 4 cm), II or IIIA NSCLC according to…. Goal: This phase III ALCHEMIST treatment trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Immunotherapy with monoclonal antibodies, such as nivolumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; National Cancer Institute (NCI).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests the combination of nivolumab and ipilimumab in adults with rare cancers to see if it can shrink tumors or slow their growth. - It includes many different rare tumor types in separate groups, plus a PD-L1–amplified cohort that uses nivolumab alone, and it measures how often tumors respond using standard criteria. - The trial also looks at safety, overall survival, and progression-free survival across cohorts. - Eligible participants must have progressed after prior therapy and generally cannot have active brain metastases or uncontrolled autoimmune disease; some cohorts have additional specific requirements or exclusions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This study tests whether nivolumab given with multi-fraction stereotactic radiosurgery, with or without ipilimumab, is safe and potentially effective for adults with recurrent WHO grade II-III meningioma that has returned after prior radiation. It is a phase I/II trial that starts with dose escalation to find a safe maximum dose, followed by a phase II portion where participants are randomized to two treatment cohorts. The main goals are safety and the maximum tolerated dose, and to assess tumor response on MRI. Secondary goals include duration of response, progression-free survival, overall survival, and exploratory immune and tumor genetic studies to identify biomarkers and resistance mechanisms. Key exclusions include recent chemotherapy or radiation to the target site, prior checkpoint inhibitor therapy, active autoimmune disease, pregnancy, and uncontrolled illness.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This trial tests olaparib, a drug that may slow tumor growth, in adults with glioma, cholangiocarcinoma, or other solid tumors that have IDH1 or IDH2 mutations and have progressed after standard treatment. - Participants are grouped into three cohorts: glioma, cholangiocarcinoma, and other IDH-mutant solid tumors, to see how they respond to olaparib. - The study aims to learn the overall response rate, how long patients live without the disease getting worse, overall survival, duration of responses, and the safety of olaparib alone. - Researchers will measure blood and tumor markers, including a molecule called 2HG, to see if these relate to treatment response. - Key exclusions include active uncontrolled brain metastases, prior PARP inhibitor therapy, pregnancy, HIV infection on antiretroviral therapy, and other serious medical conditions.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This study tests adding tazemetostat to pembrolizumab for adults with locally advanced or metastatic urothelial carcinoma (cisplatin-resistant or platinum-ineligible). - The main goal is to find a safe dose for the combination and to see how well it works, including response rate, progression-free survival, and immune-related tumor responses. - The trial also includes correlative studies using tissue and blood to learn which patients may respond. - Key exclusions include prior PD-L1 or EZH2 inhibitors, active brain metastases (unless previously treated and stable), pregnancy or breastfeeding, and certain uncontrolled illnesses or recent cancer therapies.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

- This phase II trial tests whether adding venetoclax to ASTX727 (decitabine plus cedazuridine) improves outcomes for bone marrow cancer in CMML and MDS/MPN with excess blasts compared with ASTX727 alone. - It is for adults with MDS/MPN overlap syndrome with at least 5% marrow blasts who meet certain health criteria. - Participants are randomly assigned to either ASTX727 plus venetoclax or ASTX727 alone, and the study looks at complete remission rates and other response and survival measures. - Key exclusions include pregnancy, uncontrolled central nervous system disease, significant cardiac disease, recent extensive prior MDS/MPN therapy, and other safety-related conditions (e.g., grapefruit product restrictions).

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer is being studied. Conditions: Bone Metastases, HER2-positive Breast Cancer, Liver Metastases +4 • Eligibility: Inclusion Criteria: * Participants must be women who have histological confirmation of metastatic invasive breast cancer that has metastasized outside the region of the primary tumor and axilla;…. Goal: This pilot clinical trial studies how well copper Cu 64-tetra-azacyclododecanetetra-acetic acid (DOTA)-trastuzumab positron emission tomography (PET) works in predicting response to treatment with ado-trastuzumab emtansine in patients with human epidermal growth factor receptor 2 (HER2) positive breast cancer that has spread to other places in the body. Copper Cu 64-DOTA-trastuzumab is a chemotherapy drug (trastuzumab) attached to a radioactive substance. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; City of Hope Medical Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Extreme Bipolar Androgen Therapy With Darolutamide and Testosterone Cypionate in Patients With Metastatic Castration-Resistant Prostate Cancer (ExBAT Trial) is being studied. Conditions: Prostate Cancer • Eligibility: Inclusion Criteria: 1. Written informed consent prior to beginning specific protocol procedures, including expected cooperation of the patients for the treatment and follow-up, must be obtained and documented…. Goal: This is a multi-center, open-label, phase II, single-arm trial evaluating combination of darolutamide and high testosterone doses - extreme bipolar androgen therapy (ExBAT) - in patients with metastatic castration-resistant prostate cancer (mCRPC). Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Latin American Cooperative Oncology Group.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Apalutamide, Abiraterone Acetate, and Prednisone in Treating Participants With Metastatic Castration Resistant Prostate Cancer is being studied. Conditions: Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma Without Neuroendocrine Differentiation, Stage IV Prostate Cancer AJCC v8 +2 • Eligibility: Inclusion Criteria: * Histologically or cytologically confirmed adenocarcinoma of the prostate without neuroendocrine differentiation or small cell features * Presence of metastatic disease that can be biopsied by…. Goal: This phase II trial studies how well apalutamide and abiraterone acetate work in treating participants with castration resistant prostate cancer that has spread to other places in the body (metastatic). Abiraterone acetate and apalutamide may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; M.D. Anderson Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Clinical Study of CBG131 CAR-T Cell Injection for the Treatment of CLDN18.2-Positive Advanced Gastric and Pancreatic Cancer is being studied. Conditions: Advanced Gastric and Pancreatic Cancer • Eligibility: Inclusion Criteria: 1. Age 18-70 years (inclusive) at the time of informed consent; sex unrestricted. 2. Voluntary participation: the subject (or legally authorized representative) must provide written informed…. Goal: The goal of this clinical trial is to learn if CBG131 works to treat advanced gastric cancer or pancreatic cancer in adults whose tumors are CLDN18.2-positive. It will also learn about the safety of CBG131 and find the best dose to use. Phase/Status/Sponsor: Unknown phase; NOT_YET_RECRUITING; First Affiliated Hospital of Wenzhou Medical University.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Summary not available yet.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Evaluating the Efficacy of the eNav Toolkit to Improve Colorectal Cancer Screening is being studied. Conditions: Colorectal Cancer Screening • Eligibility: Inclusion Criteria: * Patient treated at the Institute for Family Health (IFH) * Patient 45 to 75 years old * English or Spanish speaking * Able to provide…. Goal: The purpose of this research study is to evaluate the efficacy of a digital navigation tool, called the eNav to improve colorectal cancer screening uptake among patients treated at federally qualified health centers (FQHC)s. The digital navigation tool includes a website and text messaging support. Phase/Status/Sponsor: Unknown phase; ENROLLING_BY_INVITATION; Icahn School of Medicine at Mount Sinai.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

This extension study tests the long-term safety of litifilimab (BIIB059) injections in adults with active systemic lupus erythematosus (SLE) who are already on standard treatments. It enrolls people who completed the parent phase 3 studies and will receive litifilimab every 4 weeks for up to 156 weeks, with safety follow-up up to 24 weeks. Researchers will track adverse events and measure SLE symptoms over time using scoring tools like SRI, SLEDAI-2K, and BILAG-2004 to see whether the drug helps control disease activity. Key exclusions include those who ended the parent studies early, had worsening organ lupus requiring therapy changes, or used other investigational or off-label lupus drugs during the parent studies.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Study of IO102/IO103, Nivolumab, and Relatlimab in People With Melanoma is being studied. Conditions: Melanoma • Eligibility: Inclusion Criteria: 1. Age ≥ 18 years at the time of informed consent 2. Patient must be able to provide informed consent. 3. Patient must have a histologically…. Goal: The researchers are doing this study to find out whether the study vaccines, IO102/IO103, given in combination with the standard-of-care drug combination, nivolumab and relatlimab, is a safe and effective treatment for people with untreated, unresectable melanoma. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Memorial Sloan Kettering Cancer Center.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

Effect of 10 mg Xanamem on Dementia Due to Alzheimer's Disease is being studied. Conditions: Dementia Moderate, Dementia, Mild, Alzheimer Disease • Eligibility: Inclusion Criteria: * Male or female aged 50 years or older, inclusive at the time of Screening. * Clinical syndrome of mild or moderate dementia, likely to be…. Goal: Xanamem® is being developed as a potential treatment for symptomatic, early stages of Alzheimer's Disease (AD) and Major Depressive Disorder (MDD). This XanaMIA Phase 2b/3 study is to investigate the safety, tolerability, and efficacy of Xanamem in in mild or moderate dementia due to AD. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Actinogen Medical.

This summary may be inaccurate. Verify against ClinicalTrials.gov.

AI-generated summary

A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC is being studied. Conditions: Prostatic Neoplasm • Eligibility: Key Inclusion criteria * Participants must be adults ≥ 18 years of age with signed informed consent prior to participation to study * Histologically or cytologically confirmed prostate…. Goal: The purpose of this study is to evaluate the efficacy and safety of AAA617 alone (Lutetium \[177Lu\] vipivotide tetraxetan) and in combination with an Androgen Receptor Pathway Inhibitors (ARPI) in participants with PSMA-positive, castration-resistant prostate cancer and no evidence of metastasis in conventional imaging (CI) (i.e., CT/MRI and bone scans). Approximately 80 participants will be randomized. Phase/Status/Sponsor: Unknown phase; ACTIVE_NOT_RECRUITING; Novartis Pharmaceuticals.

This summary may be inaccurate. Verify against ClinicalTrials.gov.